Research Opportunities
Currently Enrolling Studies at the Frankel Cardiovascular Center:
Cardiovascular Health Improvement Project (CHIP) Biorepository
The Cardiovascular Health Improvement Project (CHIP) is collaborative research effort among physicians and researchers at the Frankel Cardiovascular Center with the goal of creating a biorepository containing blood, tissue and information from many different types of people in hopes to learn more about individuals with aortic diseases and other cardiovascular-related conditions.
What types of conditions is the study researching?
Research participants would qualify for this study if they have any of the following aortic related conditions: Thoracic aortic aneurysm, abdominal aortic aneurysm, aortic dissection, bicuspid aortic valve, Marfan’s syndrome, Loeys-Dietz syndrome, Vascular Ehlers-Danlos syndrome, coarctation of the aorta, aortitis
What is involved for a participant in our study?
1. Sign consent form online
2. Complete health surveys online
3. Complete one blood draw at a future Michigan Medicine appointment
4. Allow CHIP access to your health information
5. Allow CHIP to keep discarded tissue if you have a future heart procedure at Michigan Medicine
6. CHIP might share your coded data and sample with researchers. Your data will be coded to remove any identifying personal information.
Interested in participating or learning more? Contact us:
Principal Investigator: Marion Hofmann, MD, Phd
Email: chipstudy@med.umich.edu
Phone: 734-232-4779
Study ID: HUM00052866
Closed to Enrollment:
Exercise in Aortic Dissection Survivors
We want to find out if following an exercise program after having an aortic dissection can reduce anxiety and increase confidence to engage in activities of daily life, as well as lower blood pressure. We want to prove that moderate intensity exercises are safe for survivors of aortic dissections.
What types of conditions is the study researching?
Patients with a history of an aortic dissection
Interested in learning more? Contact us:
Principal Investigator: Marion Hofmann, MD, Phd
Email: fcvc-mi-aorta-clinicaltrial@med.umich.edu
Phone: 734-232-6180
Study ID: HUM00224748
Other Research Opportunities
Acer Therapeutics is conducting a clinical trial in the U.S. to evaluate the efficacy and safety of an investigational drug known as celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).
Acer Therapeutics is actively seeking potential participants with a confirmed diagnosis of Vascular Ehlers-Danlos Syndrome (VEDS) patients caused by a COL3A1 mutation who are interested in participating in this investigational trial.
Celiprolol is an investigational drug and therefore its safety and efficacy have not been established. There is no guarantee that celiprolol will receive health authority approval or become commercially available for treatment of Vascular Ehlers-Danlos Syndrome (VEDS).
What types of conditions is the study researching?
To pre-qualify for this clinical research study, you must meet the following criteria:
Must be greater than or equal to 15 years old
Willing to obtain a magnetic resonance angiogram (MRA) image
During screening, must have a genetic test performed, via a saliva sample, to confirm the presence of the COL3A1 mutation which will confirm a vEDS diagnosis; you will need a positive test result for Vascular Ehlers-Danlos Syndrome with a COL3A1 gene mutation.
Must be able and willing to discontinue use of beta blockers under the care of your primary physician
Should not have had an arterial rupture or dissection, uterine rupture, and/or intestinal rupture within the last 6 months
Must be willing to complete all study procedures
What is involved for a participant in our study?
If you are eligible to participate in this Vascular Ehlers-Danlos Syndrome treatment study, you will participate entirely from home. You will have study visits where a registered nurse will visit your home and study visits conducted with a registered nurse online through a telehealth visit. You will be provided instructions for taking the investigational drug which will be shipped directly to your home. During your participation in the study you will continue your regularly scheduled visits with your primary doctor(s).
Interested in participating or learning more? Contact us:
Email: vedsstudy@science37.com
Phone: 855-202-8617